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Background: Interest in health-related quality of life (HRQoL) outcome research in dermatology is increasing,
especially in the systemic treatment of psoriasis with biologic agents. In other specialties, such as oncology, the
application of a HRQoL intervention is considered to be an aid for monitoring disease and treatment over time, for
the communication with the patient, and for improving treatment outcome. However, in dermatology practice, the
application of this intervention is relatively new. Moreover, evidence on the effectiveness of a HRQoL intervention
in dermatology is missing. It is hypothesized that the application of a HRQoL intervention in dermatology practice
will have a positive impact on patients’ HRQoL as well as on doctor-patient communication.
Methods/design: In a prospective multicenter cluster randomized controlled trial, patients diagnosed with
moderate to severe psoriasis who receive biologic treatment, will be followed for 48 weeks. The study sites, and
not the patients, will be randomly allocated via a computer-based randomization system to either the intervention
(treatment with etanercept and standardized HRQoL assessment and communication) or the control group
(treatment with etanercept alone). The HRQoL intervention will include 1) the electronic assessment of the
Skindex-29, a well-studied dermatology-specific HRQoL questionnaire, and 2) the communication of the resulting
Skindex-29 data with the patient. Prior to study start, dermatologists in the intervention group will be educated
and trained in standardized HRQoL assessment and communication using the Skindex-29. At six consecutive visits,
patients at study sites in the intervention group will be asked to complete the Skindex-29 on a desk-top pc at the
clinic, just before their consultation with the dermatologist. A print-out of the completed questionnaire will be
made and, guided by this print-out, feedback on the HRQoL scores will be given during the consultation. Primary
outcome parameters are the impact of the HRQoL intervention on patients’ HRQoL, and the effect of the HRQoL
intervention on doctor-patient communication. Secondary outcomes include health status and disease severity.
Trial registration: The Netherlands National Trial Register (NTR): NTR1364.
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Patient-reported outcomes (PROs) are any aspect of a
patient’s health status that comes directly from the patient
without the interpretation of anyone other than the patient
[1]. PROs provide information on the disease or treatment
from a patient’s perspective. Examples of PROs are disease
severity, general health status, adherence to treatment, sat-
isfaction with treatment, and health-related quality of life
(HRQoL). In accordance with the definition of the World
Health Organization, HRQoL can be defined as a reflection
of patients’ physical, psychological, and social functioning
and well-being [2], and is generally considered as a key
outcome parameter. Chronic skin diseases, such as psoria-
sis, are known to have a relatively high, negative impact
on HRQoL [3]. As a result, interest in HRQoL outcome
research in dermatology is increasing, especially in the
systemic treatment of psoriasis with biologic agents.
Psoriasis is a systemic inflammatory skin disease with
increased epidermal proliferation, affecting 2% of the popu-
lation [4]. Common physical complaints of this chronic
skin disease are skin soreness, burning sensations, itching,
and joint pain. Therapies include topical treatments (for
example, topical corticosteroids), photo(chemo)therapies
(for example, UV-B and PUVA), and the conventional
systemic treatments (for example, methotrexate and cyclo-
sporin). For patients who fail or who are contraindicated
or intolerant to these conventional treatments, biologic re-
sponse modifiers, or biologics, are available, such as adali-
mumab, etanercept, infliximab, and ustekinumab. However,
since dermatological treatment can only offer a temporary
suppression or remission of symptoms, treatment efforts
may increasingly be directed towards both a decrease of
disease severity and an increase of a patient’s HRQoL.
Previous research, including studies in oncology, sug-
gested that the application of a HRQoL intervention is
considered to be an aid for monitoring disease and treat-
ment over time, for the communication with the patient,
and for improving treatment outcome [5,6]. However, in
dermatology practice, the application of a HRQoL inter-
vention is relatively new. Moreover, evidence on the ef-
fectiveness of a HRQoL intervention in dermatology is
still missing. The present study may rectify this defi-
ciency. It is hypothesized that a HRQoL intervention will
significantly improve patients’ HRQoL, and will facilitate
doctor-patient communication. In addition, this study
offers the opportunity to examine the course of HRQoL
during treatment, the mid- and long-term effects of
treatment on HRQoL, and the relationship between dis-
ease severity and HRQoL during treatment.
Methods/Design
Design of the study
This prospective multicenter randomized controlled trial
(RCT) will include a 48-week follow-up period with sixconsecutive, predefined visits: V1 (week 0; baseline visit),
V2 (week 6; 6 weeks after the first injection of etaner-
cept), V3 (week 12; 12 weeks after the first injection),
and continuing on in this manner for V4 (week 24), V5
(week 36), and V6 (week 48). For a comprehensive study
flow chart, see Additional file 1 (for the intervention
group) and Additional file 2 (for the control group). Via
ALEA, a software package to support online patient
registration and randomization in healthcare research,
the participating study sites will be cluster randomized
[www.tenalea.com]. Thus, it is not the patients, but the
study sites that will be randomly allocated to either the
intervention group (treatment with etanercept and stan-
dardized HRQoL assessment and communication) or
the control group (treatment with etanercept alone).
With this computer-based system, allocation of conceal-
ment will be assured. Random assignment of patients
instead of study sites was considered, but rejected due
to practical limitations, that may cause a contamina-
tion effect.
In order to create equal comparison groups, the
randomization will be stratified by four clusters: aca-
demic centers versus non-academic centers, and centers
naive to HRQoL assessment and communication versus
centers not (completely) naive (Figure 1a). Study sites
that have participated in a national Working Group
Quality of Life Assessment in Dermatological Practice
(2007 to 2008) will be considered not naive, since these
sites do have a high interest in, and are involved in
HRQoL assessment at their local clinical settings. This
will result in a randomization scheme consisting of three
blocks (Figure 1b). Herewith, the sizes of the interven-
tion and control group will be similar, taking an equal
distribution of type of study sites into account.
Since the intervention concerns both patients (for ex-
ample, completion of the intervention questionnaire)
and dermatologists (for example, providing feedback on
the HRQoL scores of the intervention questionnaire),
dermatologists in the intervention group will be edu-
cated and trained in standardized HRQoL assessment
and communication prior to study start, during the
‘Intervention Training’ session on group level. The aim
of this training is to enable dermatologists in the inter-
vention group to adequately discuss HRQoL scores, as
well as aspects of HRQoL, such as coping behavior and
disease management. As a result, dermatologists will be-
come more familiar and, thereby, comfortable with
HRQoL assessment and communication in clinical prac-
tice. To this aim, the Intervention Training will include
evidence-based background information on the con-
struct HRQoL, its relevance to clinical practice, and
the impact of psoriasis on HRQoL [5-10]. Dermatolo-
gists will be trained in the electronic assessment of
the intervention questionnaire, the Skindex-29, and the
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Figure 1 Clustered block randomization (a). Clustering of the participating study sites (N=18). (b). Block randomization of the clustered study
sites (N=18).
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coping behavior and disease management will be provided.
In this study design neither the patients nor the der-
matologists can be blinded to the intervention.Setting
The study will be conducted at 18 outpatient dermatol-
ogy clinics in the Netherlands. Psoriasis patients will be
consecutively invited to participate in the study after a
medical decision is made to start biologic treatment with
etanercept. Patients eligible for the study are diagnosed
with a moderate to severe psoriasis (that is, a PsoriasisArea and Severity Index (PASI) of ≥8), and are 18 years
or older at the time of informed consent. Patients who
are mentally and/or physically unable to complete the
study questionnaire(s), who speak the Dutch language
insufficiently to fully understand and complete the inter-
vention and/or study questionnaire(s), or who are not
willing or not able to discuss HRQoL-issues, will be
excluded from participation. A patient information form
will be handed to all potential participating patients.
Written informed consent needs to be obtained from all
participating patients prior to study start.
This study is registered in the Dutch Trial Register
(NTR1364). The study protocol has been reviewed and
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(Centrale Commissie Mensgebonden Onderzoek - CCMO)
(NL24494.018.08 BI), and reviewed by the Medical Ethics
Committee of the Academic Medical Center, University of
Amsterdam (EC AMC) (MEC 08/302). The EC AMC
exempted this study for ethical approval. A written con-
firmation of this statement was given by the EC AMC
(Ref: MEC 08/302# 08.17.1716; MEC 08/302# 08.17.1933).
The study will be conducted in accordance with the
applicable laws and regulations following the Declaration
of Helsinki protocols.
Participants
Psoriasis patients who will receive etanercept treatment
by prescription from their dermatologists will be asked
to participate in the study [11-14]. Thus, all included
patients of both the intervention and control group will
receive etanercept, as a constant factor, in accordance
with routine clinical practice and, ideally, following the
Dutch treatment guidelines for psoriasis: a PASI ≥8; in-
effective or contra-indications to PUVA treatment twice
weekly for 10 weeks; ineffective or contra-indications to
treatment with cyclosporine 3-5 mg/kg/day for 16
weeks; and/or ineffective or contra-indications to treat-
ment with methotrexate 22.5 mg/day for 16 weeks [15].
The per-protocol dose regimen of etanercept in week 0
to 12 (V1 to V3) is in accordance with the current
Dutch summary of product characteristics (SmPC),
namely: 2 x 50 mg/week. Depending on the PASI as
measured at week 12 (V3), patients either discontinue
treatment in case of PASI <50, or continue treatment
during week 12 to 24 (V3 to V4). This treatment phase
is called the induction phase. If PASI <75, patients will
continue treatment with etanercept with 2 x 50 mg/
week; if PASI ≥75, patients will continue with 2 x 25 or
1 x 50 mg/week. However, current clinical practice
showed that a growing number of Dutch dermatologists
continue treatment directly after the maximum treat-
ment period of 24 weeks. Supporting evidence was
found for an entire dosage regimen (week 0 to 48) in the
British Association of Dermatologists Guidelines, in the
German guidelines for systemic therapy, and in a study
on the long-term safety and efficacy of 2 x 50 mg/week
[16-19]. Per study protocol, patients will continue treat-
ment during week 24 to 48 (V4 to V6), with 2 x 25 or 1
x 50 mg/week, which is called the maintenance phase
(see Figure 2). The dosing schedule as suggested per
protocol will be used as a guide for dermatologists.
However, the actual dosing schedule to be given to
patients will depend on routine clinical practice and the
dermatologists’ prescriptions. Previous treatment with
any biologic is allowed, taking the applicable wash-out
period into account prior to treatment with etanercept.
Concomitant topical treatment will be permitted.Intervention
The HRQoL intervention in this study consists of 1) the
electronic assessment of the Skindex-29, a well-studied
dermatology-specific HRQoL questionnaire, and 2) the
communication of the resulting Skindex-29 data with
the patient. The Skindex-29 consists of 29 questions, or
items (for example items on pain, itch, embarrassment,
frustration, social life, and interaction with others).
Questions concern patients’ perception of the impact of
the skin disease on aspects of HRQoL during the past
week. These 29 items form three domains: symptoms,
emotions, and functioning. Responses are given on a
five-point response scale (ranging from ‘never’ to ‘all the
time’), where scores are transformed to a 100-point scale,
and domain and overall scores are being calculated by
averaging responses to items in a given domain. Higher
scores are indicating lower levels of HRQoL [20,21]. Sev-
eral reviews suggested that the Skindex-29 is considered
to be the instrument of choice in dermatology [9,22]
Before study start, dermatologists in the intervention
group will be supported in the installation of the elec-
tronic version of the Skindex-29 on a desktop pc at the
study sites, including a connection with a printer device.
Prior to each consultation, patients in the interven-
tion group will be asked to complete the Skindex-29
on a desk-top pc at the clinic. Patients will receive instruc-
tions from a dermatologist, or a designated representative,
on how to complete this electronic questionnaire, without
providing any information on the content or answers of
the items. After completion, both the patient and the
dermatologist will receive a print-out of the question-
naire, including the answers given and a matrix visually
displaying the domain and overall scores. Guided by this
print-out, the dermatologist will be able to systematically
discuss the Skindex-29 answers and scores with the
patient. In addition, and during consecutive consulta-
tions, the patient and the dermatologist will also be able
to follow the HRQoL-scores over time as being displayed
by this matrix showing repeated measurements.
The HRQoL intervention will be supported by patient
information on quality-of-life, coping behavior, and dis-
ease management. At the first consultation, dermatolo-
gists will be instructed to provide two brochures to the
patient; one with general information on HRQoL, and
one on coping with and the management of psoriasis.
At the second consultation, patients will receive another
brochure about the treatment of psoriasis, including a
chapter on HRQoL. In addition, a quality-of-life issue of
a patient magazine from the Dutch Psoriasis Foundation
will be provided to patients as well. At the third consult-
ation, patients will receive a DVD on coping with psoria-
sis. At the fourth consultation, patients will receive a
book entitled: ‘Psoriasis - Image, Experience, Treatment’,
and patients will be instructed to read chapter 15: ‘The
2x50 mg/week 
Week 12-24 





2x50 mg/week 2x25 or 1x50 mg/week 
Maintenance Phase 
Week 24-48 
2x25 or 1x50 mg/week 
Figure 2 Per-protocol dose regimen schedule for etanercept in the treatment of moderate to severe psoriasis.
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patients will be asked to read chapter 16: ‘Coping with
psoriasis’. Patients will be instructed to read and to
watch the applicable patient information at home and
prior to their subsequent consultation. The patient infor-
mation can be stored in a study specific binder called
‘My Quality of Life’.
Additionally, all patients, both in the intervention and
control group, will be asked to complete a diary to rec-
ord the etanercept injections. These diaries will be used
for monitoring the drug compliance.
Comparison
Patients in the control group will not receive the HRQoL
intervention, but will receive etanercept treatment only.The consultation will be conducted according to routine
clinical practice, or usual care. Dermatologists in the con-
trol group will be asked to stay naive to HRQoL assess-
ment and communication during the course of this study;
that is, they are not to implement electronic HRQoL as-
sessment with and communication about the Skindex-29
during their consultations with study participants.Outcome measures
The primary outcome parameters in this study are 1) the
impact of the HRQoL intervention on patients’ HRQoL
and 2) the effect of the HRQoL intervention on doctor-
patient communication. Since the Skindex-29 is used as
the intervention questionnaire, the impact on HRQoL
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HRQoL questionnaire, namely the Dermatology Life
Quality Index (DLQI). The DLQI consists of ten items
and each item is scored on a four-point scale ranging
from ‘not at all/not relevant’ to ‘very much’. Scores of
individual items (0 to 3) are added to yield a total score
(0 to 30). Higher scores mean greater impairment of
a patient’s HRQoL [23,24]. A study-specific, two-
dimensional communication questionnaire will be used
to measure the effect on doctor-patient communication.
This communication questionnaire consists of two parts,
measuring: 1) the satisfaction with doctor-patient com-
munication and 2) the quantity of HRQoL communica-
tion during consultations. With approval from the
authors, the first part of the communication question-
naire is a slightly adapted version of the Patient Satisfac-
tion Questionnaire and includes items on satisfaction
with information, (emotional) support, communication,
and fulfillment of needs [25]. Answers are given on a vis-
ual analogue scale (VAS) ranging from 0 to 10, for ex-
ample, ‘not at all satisfied’ to ‘very much satisfied’, or ‘not
at all important’ to ‘very much important’. The cut-off
point for satisfaction will be 6.0 (60%). The second part
of the communication questionnaire includes items on
symptoms, mood or emotions, social functioning, and
overall quality-of-life. Patients will be asked if these
aspects were discussed during the patient consultation
or not, by ticking ‘yes’, ‘no’, or ‘I don’t know’. The com-
munication questionnaire was successfully pilot tested in
seven in-patients with psoriasis at the Academic Medical
Center, Amsterdam.
The secondary efficacy endpoints include health status
and disease severity. Health status will be measured with
the Medical Outcomes Study 36-item Short-Form Gen-
eral Health Survey (SF-36), a well-established, eight-di-
mensional, generic HRQoL instrument [26,27]. The
items represent issues relevant to health status, and re-
late to the past four weeks. The SF-36 will be completed
at week 0 (V1), week 24 (V4), and week 48 (V6) by
patients in both the intervention and control group. Dis-
ease severity will be measured with the PASI, the most
widely used instrument for the measurement of the se-
verity of psoriasis [28], and with an investigator global
assessment (IGA) and a patient global assessment
(PGA). The IGA is asking dermatologists: ‘In your opin-
ion, how severe is your patient’s current skin condition?’,
and the PGA is asking patients: ‘How severe is your
current skin condition?’. Answers can be given on a five-
point scale, ranging from ‘not severe’ to ‘very severe’. All
patients will be asked to complete this set of question-
naires at the end of each patient consultation.
In addition, two evaluation questionnaires will be
introduced to measure 1) aspects on satisfaction and 2)
aspects on the feasibility of HRQoL assessment andcommunication in dermatology practice. First, at week
24 (V4) and week 48 (V6), an overall evaluation ques-
tionnaire will be handed to dermatologists in the inter-
vention group, and to patients in both the intervention
and the control group. This questionnaire comprises a
study-specific questionnaire about 1) satisfaction with
the treatment process, including doctor-patient commu-
nication, and 2) satisfaction with treatment outcomes.
For example, ‘How satisfied are you about the conversa-
tions you have had with your doctor/patient?’. Answers
are given on a VAS, ranging from ‘not at all satisfied’ to
‘very much satisfied’. Second, after each patient consult-
ation, dermatologists in the intervention group will be
asked to answer questions on aspects of feasibility, such
as completion time, duration of the consultations, and
(the number of ) aspects of HRQoL discussed during the
consultations. Dermatologist in the control group will
only be asked about the duration of the consultations.
Data collection
A Case Report Form (CRF) will be provided for each pa-
tient. All protocol-required information that needs to be
collected during this study will be entered by the derma-
tologist, or a designated representative. Baseline charac-
teristics will be obtained at visit 1 (week 0).
Safety
All patients will be monitored for safety during their
participation in the study, including adverse events
(AEs) and premature discontinuation from the study.
AEs are defined as any undesirable experience occurring
to a patient during the study, whether or not considered
related to etanercept. Serious adverse events (SAEs) will
be recorded by the responsible dermatologist and
reported within 24 hours of notification to the trade
holder of etanercept. According to the Dutch Personal
Data Protection Act, all data will be handled confiden-
tially and anonymously, and will be stored for 15 years
after study close out (that is, last patient last visit).
Analysis
Power calculation
The sample size calculation is based on the two primary
outcome parameters and its corresponding outcomes
measures, namely the DLQI and the communication
questionnaire.
Based on previous research, we will expect a HRQoL
improvement, as measured with the DLQI, of 1.0 stand-
ard deviation (SD) in the intervention group and of 0.7
in the control group. We expect a communication effect
size of 0.8 (that is, an improvement of 0.8 SD) in the
intervention group, and of 0.4 in the control group.
With 100 patients in each group, the power to detect a
longitudinal effect would be larger than 99%, assuming a
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the correlation between scores at baseline and end of in-
duction phase) of 0.5.
The power to detect differences in longitudinal DLQI
effects between the intervention and control group will
be 56%. In case of one-tailed testing, the power to detect
differences in longitudinal DLQI effects between the
intervention and control group will be 68%. A mean
DLQI score of 12.0 (SD 7.0), and a clinically meaningful
improvement of 5 points is expected. In the intervention
group, an additional improvement of 2 points (effect
size: 0.3) is expected.
The power to detect differences in longitudinal com-
munication effects between the intervention and control
group is 80%. The power calculation is conservatively
based on an estimate of 200 patients; that is, it is based
on 100 patients per group and an expected withdrawal
rate of approximately 20%.
Statistical analysis
Statistical analyses will comprise two components: 1) the
induction phase analysis (week 0 to week 24) and 2) the
maintenance phase analysis (week 24 to 48).
The induction phase analysis will concern all patients
who receive any treatment with etanercept, who respond
to the study questionnaires on HRQoL, communication,
health status, and disease severity, and of whom PASI is
assessed at baseline. The last visit of patients who may
discontinue from treatment for any reason, including
patients who will not meet the criteria to continue treat-
ment with etanercept after week 12 (PASI <50), will be
considered as End of Induction Phase (week 24).
The maintenance phase analysis will concern all
patients who receive any treatment with etanercept after
week 24, who respond to the questionnaires, and of
whom PASI is assessed at week 24. The last visit of
patients, who may discontinue from treatment for any
reason, will be considered as End of Maintenance Phase
as well as End of Treatment (week 48).
All analyses will be performed on an intention-to-treat
basis. In any case where patients prematurely discon-
tinue from treatment, they will be asked to complete an
Early Termination visit. The content of this visit is simi-
lar to V6, and data will be handled based on the ‘last
value carried forward’ principle.
Patient characteristics will be described by randomized
groups. Categorical data will be summarized as frequen-
cies and percentages. Continuous data will be summar-
ized by means and standard deviations. Linear mixed
model analysis will be used to investigate the course of
the outcomes (that is, DLQI scores for HRQoL; commu-
nication scores for doctor-patient communication; SF-36
scores for health status; and PASI, IGA, and PGA for
disease severity), and to test the effects of possibleexplanatory variables on the outcome variables. Longitu-
dinal models will have a random intercept to account for
individual differences at baseline, fixed regression coeffi-
cients for each of the measurement occasions following
baseline, for the intervention effect, for study sites (to
account for differences between sites), and for possible
other explanatory variables (such as age and sex). We
will investigate which longitudinal structure is most ap-
propriate, whether one or more of the fixed regression
coefficients should be considered random, and whether
there are interaction effects.
Discussion
This study investigates the impact of HRQoL assessment
and communication on patients’ HRQoL, and its effect
on doctor-patient communication. To the best of our
knowledge, this is the first RCT that examines the effect-
iveness of such HRQoL intervention in patients with
moderate to severe psoriasis.
Several studies in, for example, oncology showed a posi-
tive impact on patients’ well-being as well as a significant
increase in the discussion of symptoms. Valderas and col-
leagues (2008) [29] conducted a systematic review on the
impact of PRO assessment in clinical practice in different
clinical settings, such as internal medicine, oncology, and
primary care. They concluded that, because the studies
analyzed were heterogeneous in the types of setting,
patients, intensity of intervention, and diversity of out-
comes, no apparent conclusion could be drawn. In
addition, the included studies were of limited methodo-
logical quality. Despite this, they found grounds for
optimism, and they recommended well-designed and well-
conducted future randomized studies [29].
A major strength of this study is that clinical staff,
rather than research staff, is responsible for the imple-
mentation of the intervention. Herewith, the HRQoL
intervention is implemented in a regular clinical setting.
In addition, the HRQoL intervention will be evaluated in
multiple clinical settings with diverse doctor and patient
samples.
A few limitations of this study need to be addressed.
First, our patient sample cannot be considered truly rep-
resentative for psoriasis patients in general since only
psoriasis patients who are being treated with etanercept
will be asked to participate in the study. This may affect
the external validity. Treatment with other biologics was
considered, but rejected due to methodological limita-
tions, such as route of administration, dosing schedule,
and corresponding consultations to the dermatologists,
that may affect the outcome. Second, the improvement
of patients’ HRQoL over time may be due not only
to the intervention, but also to their psoriasis treat-
ment with a biologic [30,31]. However, an additional im-
provement on top in HRQoL is expected because of the
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nor the patients can be blinded in this study design,
which may affect the internal validity. And lastly, we
used block randomization to generate equal comparison
groups with respect to academic versus non-academic
centers and centers being naive versus not-naive to
HRQoL assessment. However, since only two academic
centers agreed to participate, with one center being naive
and the other not naive to HRQoL assessment, the inter-
vention and control conditions in the academic centers
are not comparable with respect to this latter variable.
The findings to be reported in this study are the first
in dermatology. Therefore, some caution is needed when
interpreting the results of this study, and confirmation
through future study results is necessary. Nevertheless,
the results of this study may be encouraging for further
research and future use in dermatology practice.
Trial status
Patient recruitment is ongoing.
Additional files
Additional file 1: Study flow chart intervention group.
Additional file 2: Study flow chart control group.
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